Page last updated: 2024-12-11

evocarpine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

evocarpine: structure given in first source; RN given refers to (Z)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5317303
CHEMBL ID5173740
CHEBI ID80821
SCHEMBL ID15944383
MeSH IDM0164862

Synonyms (14)

Synonym
15266-38-3
evocarpine
C16956
1-methyl-2-[(z)-tridec-8-enyl]quinolin-4-one
AKOS016010722
(z)-1-methyl-2-(tridec-8-en-1-yl)quinolin-4(1h)-one
CHEBI:80821
SCHEMBL15944383
1-methyl-2-[(z)-8-tridecenyl]-4-(1h)-quinolone
CHEMBL5173740
Q27149864
MS-25177
CS-0018549
HY-N2060

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Total plasma clearance (CL), volume of distribution (Vd), and half-life (T1/2) of evocarpine were 60 ml/min."( Pharmacological properties of galenical preparation. XV. Pharmacokinetics study of evocarpine and its metabolite in rats.
Chen, XF; Kanemaki, S; Kano, Y; Komatsu, K; Zong, Q, 1991
)
0.73

Dosage Studied

ExcerptRelevanceReference
" Pharmacokinetics of evocarpine after intravenous injection was expressed in a one-compartment model, showing a linear elimination of plasma evocarpine up to a dosage of 75 mg/kg."( Pharmacological properties of galenical preparation. XV. Pharmacokinetics study of evocarpine and its metabolite in rats.
Chen, XF; Kanemaki, S; Kano, Y; Komatsu, K; Zong, Q, 1991
)
0.83
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
quinolinesA class of aromatic heterocyclic compounds each of which contains a benzene ring ortho fused to carbons 2 and 3 of a pyridine ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1872630Antibacterial activity against Mycobacterium tuberculosis H37Ra assessed as inhibition of bacterial growth incubated for 72 hrs by microbroth dilution method2022European journal of medicinal chemistry, Mar-15, Volume: 232Quinoline heterocyclic containing plant and marine candidates against drug-resistant Mycobacterium tuberculosis: A systematic drug-ability investigation.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (12.50)18.7374
1990's3 (37.50)18.2507
2000's1 (12.50)29.6817
2010's2 (25.00)24.3611
2020's1 (12.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.02

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.02 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.92 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.02)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]